TELA Bio, Inc. reported preliminary financial results for Q3 2024, estimating revenue of $19.0 million, up from $15.1 million in Q3 2023, with a gross margin of approximately 68%. The company also noted a decrease in cash to $17.3 million from $46.7 million at the end of 2023 and expects to reduce operating expenses by $5.0 to $10.0 million annually starting in 2025.